7 citations
,
May 2020 in “Dermatologic Therapy” This review explores the role of dermatologists in COVID-19 research, discussing various topics such as skin manifestations, treatments, and skin-related effects of PPE, but reports no new clinical results.
6 citations
,
January 2013 in “Urology” This case report describes an 8-year-old child with penile tourniquet syndrome due to a constricting thread, which led to partial distal penile amputation and required surgical intervention.
6 citations
,
May 1987 in “Acta dermato-venereologica” In this study, analysis of hair root status showed similar abnormalities in both primary and secondary syphilis patients, though it remains unclear if these are specific to syphilis.
4 citations
,
January 1991 in “Journal of dermatological treatment” This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.
3 citations
,
June 2022 in “Journal of The American Academy of Dermatology” In this study, the COVID-19 pandemic was associated with increased diagnoses of acne and telogen effluvium, particularly among patients with COVID-19, at a New York City hospital system.
2 citations
,
July 2016 in “Pharmacopsychiatry” This case report describes a non-mosaic Turner-Syndrome individual with global cerebral atrophy, significant cognitive impairment, and severe treatment-resistant schizophrenia.
2 citations
,
March 2004 in “Journal of the American Academy of Dermatology” Minoxidil 5% solution quickly improves hair growth and density with minimal side effects.
1 citations
,
January 2023 in “Middle East Research Journal of Pharmaceutical Sciences” This review discusses the mechanisms and grading challenges of acne vulgaris, highlighting the need for better treatment strategies and reports no new experimental results.
1 citations
,
October 2016 This discussion highlights the genetic and phenotypic variability in inherited hair disorders and emphasizes the importance of accurate diagnosis due to potential systemic manifestations; no new clinical results are reported.
May 2026 in “SJ Gynecology and Obstetrics Africa” In this study, younger women with PCOS showed a 27% prevalence of abnormal glucose tolerance, with higher rates among those who are obese, have central adiposity, acanthosis nigricans, or a family history of diabetes.
April 2026 in “Brain Sciences” This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.
February 2026 in “Research Society and Development” This review highlights the multiple physical and psychological impacts of polycystic ovary syndrome in reproductive-aged women and underscores the importance of early medical evaluation and lifestyle changes for effective treatment.
January 2026 in “Magazine Portal Bibliotech Digital (Universidad Nacional de Colombia)” This study reviewed the literature on Minoxidil and finasteride for androgenetic alopecia, finding both drugs effective but noting potential side effects, with combined therapy possibly enhancing efficacy and patient adherence while reducing adverse effects.
December 2025 in “Cureus” This case report highlights the importance of considering SLE in young male patients with unexplained inflammatory musculoskeletal symptoms, as systemic inflammation was identified and symptoms improved with hydroxychloroquine.
November 2025 in “Gynecological Endocrinology” This review discusses coordinated management strategies for polycystic ovary syndrome across various levels of care but reports no new clinical results.
October 2025 in “University of Zadar Institutional Repository” This article reviews the association between androgenic alopecia and metabolic syndrome, highlighting the importance of early diagnosis and lifestyle changes to manage associated health risks, but reports no new clinical results.
September 2025 in “The Open Dermatology Journal” In this study, the Tibot AI application showed high diagnostic accuracy for adnexal and pigmentary disorders and cutaneous tumors in dermatology, but was less effective for immunological disorders and infestations, suggesting the need for further dataset refinement.
July 2024 in “The Journal of Dermatology” This study among patients with severe alopecia areata in South Korea found that 93.4% received pharmacological treatment, with 71.0% achieving hair regrowth and 59.2% experiencing major regrowth, but highlighted a critical unmet need for more effective treatment strategies.
June 2024 in “British Journal of Dermatology” This narrative focuses on the experiences of two women with permanent chemotherapy-induced alopecia, highlighting the severe psychological and social impact along with dissatisfaction over pre-treatment information about hair loss, which they initially believed to be temporary.
June 2024 in “Journal of Dermatology & Cosmetology” This comparison study identified non-shaven FUT long hair (FUL) restoration as potentially offering more aesthetic benefits and fewer scars than FUE or conventional FUT for treating various types of alopecia.
May 2024 in “Journal of Education, Health and Sport” This review article highlights the complexity of treating folliculitis decalvans, emphasizing the role of systemic antibiotics like rifampicin and clindamycin as common treatments, while also discussing promising novel therapies, including biological agents, that require further clinical trials to assess their effectiveness and safety.
March 2024 in “Clinical and experimental dermatology” This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.
December 2023 in “Journal of dermatology” This study examined the clinicopathologic and trichoscopic characteristics of keratosis follicularis spinulosa decalvans and identified terminal hair involvement and follicular hyperkeratosis as key diagnostic features.
November 2023 in “Global Medical Genetics” This case report describes a 1-month-old male infant with Netherton syndrome, characterized by severe hypernatremia, skin and scalp issues, highlighting the syndrome's complications, including growth retardation and infection risks in early life.
July 2023 in “Health science reports” In this study, researchers examined the prevalence of comorbid conditions among 402 alopecia areata patients, finding that hypothyroidism was notably more frequent in women, while hyperlipidemia was more common in men, with overall thyroid function testing suggested for these patients.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” This case report describes a 15-year-old girl with features of Becker naevus syndrome, highlighting the importance of DNA analysis from skin to confirm the diagnosis after 9 years of symptoms.
May 2023 in “Dermatology online journal” This review summarizes the psychosocial impact of common pediatric skin conditions like vitiligo, psoriasis, and alopecia areata, highlighting increased risks of anxiety, depression, and quality of life impairment for affected children and their caregivers, and underscores the need for improved support and research on interventions.
March 2023 in “Journal of Education, Health and Sport” Among women with polycystic ovary syndrome, this study observed a median depression incidence of 36.6%, significantly higher than the 14.2% reported in women without the syndrome.
January 2023 in “Sibirskij medicinskij vestnik” This analysis explores possible causes of menstrual irregularities in women with PCOS following COVID-19, but reports no new clinical findings.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study explores how EGFR signaling impacts skin inflammation and follicular integrity during hair eruption, aiming to identify druggable pathways to mitigate skin inflammation in cancer patients receiving EGFR inhibitors.